DOCSLIB.ORG

Studies on the Pharmacogenetic Aspect#Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Studies on the Pharmacogenetic Aspect#Of STUDIES ON THE PHARMACOGENETIC ASPECT#OF BRONCHOGENIC CARCINOMA FfESMOKERS by RIAD AYESH A thesis submitted for the degree of Doctor of Philosophy University of London ProQuest Number: 10610830 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10610830 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 This work is dedicated to the memory of my parents. "No character owes its existence to inheritance alone or to environmental factors alone. No character is either innate or acquired : all are both, but in varying degrees because the degree of penetrance that genes show can be very variable." Sir Gavin De Beer (1966) Page 1 Contents Page ABSTRACT 2 ACKNOWLEDGEMENTS 3 LIST OF TABLES 4 LIST OF FIGURES 8 CHAPTER ONE Introduction 10 CHAPTER TWO Pharmacogenetics, cytochrome P-450 genes and genetic susceptibility to bronchogenic carcinoma in smokers. 56 CHAPTER THREE Debrisoquine oxidation phenotypes as markers for susceptibility to bronchogenic carcinoma in smokers. 88 CHAPTER FOUR Genetic polymorphism of mcphenytoin 4-hydroxylasc in lung cancer patients. A comparative study with debrisoquine 4-hydroxylase. 150 CHAPTER FIVE Comparison of phenotypes for metabolism of antipyrine and debrisoquine as indicators of lung cancer risk in smokers. 172 CHAPTER SIX General discussion and concluding remarks. 203 BIBLIOGRAPHY 210 APPENDICES 277 Page 2 ABSTRACT Bronchial carcinoma is not an inevitable consequence of smoking cigarettes. This thesis seeks to determine whether any one or more of the well established oxidative polymorphisms might directly control the biological response to cigarette smoking and/or environmental agents. 1. In the first part of the study, two groups (I and II) of European Caucasian patients were investigated with debrisoquine. Patients with lung cancer (n=245) and controls with airflow limitation (n=234) were similar in age (66.5 ± 7.4 (mean + SD) and 67.2 + 3.2 respectively), sex ratio ((M/F) 1.82, 1.89) and smoking history (60.3 + 24.0 (mean + SD), 59.4 + 21.1 pack year). Debrisoquine 4-hydroxylation showed major differences between lung cancer and control series. The metabolic ratios (MR) for smoking controls included 21 recessives and were distributed across the full range of values. On the other hand, the metabolic ratios for cancer patients contained only 4 recessives and were aggregated towards the left end of the spectrum of metabolic ratios. The relative risk for lung cancer for the extensive metabolisers of debrisoquine (MR<1) is 13 (95% Cl : 4.0-43.3). Within this group, the risk for lung cancer increases further with possible and likely exposure to both asbestos and polycyclic aromatic hydrocarbons. The increased risk among this group with likely asbestos or polycyclic aromatic hydrocarbon exposure, is 35-fold and 17-fold respectively compared to non exposed poor and intermediate phenotypes. The debrisoquine hydroxylation status associated with lung cancer risk does not appear to be altered in any way by cigarette smoke or by the direct influence of the tumour mass. 2. A study was undertaken to eliminate the possibility of an enhanced, oxidative metabolism in lung cancer patients being an effect of the disease rather than associated with its cause. Two groups of patients (lung cancer (n=24) and controls (n=27) were investigated with both debrisoquine and mephenytoin. The % mephenytoin recovery as 4-hydroxymephenytoin was variable in both groups but statistically insignificant, 19 ± 11.8 mean ± SD 21.6 + 8.1 for cancer and controls respectively. The data showed no correlation between the debrisoquine metabolic ratios and the % mephenytoin recovery (rs=0.21 P>0.10). 3. A third study was undertaken to investigate the hepatic oxidation rates in lung cancer patients (n=30) and controls (n=29) as measured by antipyrine metabolism and to investigate the ability to metabolise both debrisoquine and antipyrine in both groups. The antipyrine clearance was almost identical in the two groups with mean + SD 2.9 + 0.46 L/h, 3.0 + 0.5 in cases and controls respectively. The results also showed that there is no difference in the pharmacokinetic parameters of antipyrine between both extensive and poor metabolisers for debrisoquine hydroxylation. 4. The results of this thesis suggest a) that cigarette smokers who arc extensive metabolisers of debrisoquine are at an elevated risk of developing lung cancer, b) additive risk between the ability to extensively metabolise debrisoquine and occupational exposure to lung carcinogens in male smokers, c) the metabolic oxidation phenotypes may serve with other genetic markers for assessing susceptibility to lung cancer. 5. An agenda for subsequent investigations is proposed. Page 3 ACKNOWLEDGEMENTS I would like to thank Professor R.L. Smith for allowing me to work in his Department and for his tremendous help and advice. I would like to thank Dr. M. Hetzel for his unstinted help and kindness and endless encouragement throughout the course of this work. I am deeply grateful to Professor J.R. Idle for his thoughtful and enthusiastic help, guidance and supervision throughout this study. My special thanks to Dr. N.S. Oates for his help with computer graphics and data analysis. My thanks also to Dr. J. Ritchie, Mr. M. Crothcrs for their help in analysing the urine and plasma samples. My thanks also to both Mr. L.A. Wakile and Mr. J. O’Gorman for their support throughout my work. Finally, I am most grateful to Mrs. A. Stolinska for typing this thesis. Page 4 LIST OF TABLES Page Table 1.1 Histological classification of lung tumours. 19 Table 1.2 Histological classification of bronchogenic carcinoma. 20 Table 1.3 Relative risk of lung cancer in large cohort studies among men smoking cigarette and other types of tobacco. 27 Table 1.4 Toxic agents in the gaseous phase of tobacco smoke. 35 Table 1.5 Carcinogenic agents in the particulate phase of tobacco smoke. 36 Table 1.6 Some of the co-carcinogenic agents in the particulate phase of tobacco smoke. - 37 Table 1.7 Known suspected agents of occupational cancer of the lung and their relation to various histological types. 41 Table 1.8 Death rate per 100,000/population in various countries due to lung cancer. 51 Table 1.9 Death rate per 100,000/population in the UK due to lung cancer. 52 Table 1.10 The incidence and mortality rate due to the most common type of cancer in England and Wales. 53 Table 2.1 Examples of known genetic polymorphisms in human and their mode of inheritance. 62 Table 2.2 Associations of some diseases of unknown etiology with human genetic polymorphisms. 63 Page 5 Page Table 2.3 Polymorphisms of human drug metabolising pathways. 74 Table 2.4 Main causes of cancer in the U.K. 77 Table 2.5 Geographical distribution of relative risk of lung cancer by smoking category. 85 Table 3.1 Host factors and human cancer. 90 Table 3.2 The frequency of deficient trait of debrisoquine 4-hydroxylation in various populations. 97 Table 3.3 General characteristics of both cases and controls (Study number one). 110 Table 3.4 Selected characteristics of lung cancer patients and airflow limitation controls. 119 Table 3.5 The distribution of study group members by age, sex and disease. 119 Table 3.6 The measured parameters for both blood chemistry and haematology of the study group patients. 120 Table 3.7 The number of individuals in both cases and controls which have measured routine haematology and clinical chemistry parameters above or/below the clinical range for each parameter. 122 Table 3.8 The distribution of debrisoquine metabolic ratios in association with histology subtypes, sex, % debrisoquine recovery and smoking (PY). 126 Table 3.9 The number of individuals on each drug used by both groups of patients. 127 Page 6 Page Table 3.10 Relative risk of developing lung cancer in smokers by debrisoquine metaboliser status. 129 Table 3.11 The relative risk for lung cancer among extensive metabolisers of debrisoquine by sex and cell type. 130 Table 3.12 The relative risk of lung cancer in maleby occupational exposure to lung carcinogens. 131 Table 3.13 The relative risk (RR) of lung cancer in males by occupational exposure to lung carcinogens and by debrisoquine metabolic ratios. 132 Table 3.14 The influence of cigarette smoking on the debrisoquine metabolic ratios. 133 Table 3.15 The range of clinical syndromes as a consequence of hormones production by bronchogenic carcinoma. 138 Table 3.16 Ectopic hormones produced by bronchogenic carcinoma and other tumours. 139 Table 3.17 Drugs of which one or more metabolic pathways have been reported to co-segregatc with debrisoquine polymorphism as assessed in in vitro and or in vivo studies. 145 Table 3.18 Syggested inherited factors in lung cancer development. 148 Table 4.1 Factors causing interindividual differences in the rate of drug metabolism. 152 Table 4.2 Inter-ethnic differences in pooor metaboliser incidence of mephenytoin oxidation. 157 Page 7 Page Table 4.3 Substrates with inhibiting potency towards mephenytoin 4-hydroxylation in vitro. 159 Table 4.4 General characteristics of lung cancer patients and controls (Mephenytoin Study). 164 Table 4.5 Selected characteristics of lung cancer cases and control (Mephenytoin Study).
Load more

Recommended publications
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Inhibition of Monoamine Oxidase in 5
    Br. J. Pharmac. (1985), 85, 683-690 Inhibition ofmonoamine oxidase in 5- hydroxytryptaminergic neurones by substitutedp- aminophenylalkylamines Anna-Lena Ask, Ingrid Fagervall, L. Florvall, S.B. Ross1 & Susanne Ytterborn Research Laboratories, Astra Likemedel AB, S-151 85 Si3dertilje, Sweden 1 A series ofsubstituted p-aminophenethylamines and some related compounds were examined with regards to the inhibition ofmonoamine oxidase (MAO) in vivo inside and outside 5-hydroxytryptamin- ergic neurones in the rat hypothalamus. This was recorded as the protection against the irreversible inhibition of MAO produced by phenelzine by determining the remaining deaminating activity in the absence and presence ofcitalopram using a low (0.1 yIM) concentration of ['4CJ-5-hydroxytryptamine (5-HT) as substrate. 2 Some ofthe phenethylamines were much more potent inside than outside the 5-hydroxytryptamin- ergic neurones. This neuronal selectivity was antagonized by pretreatment of the rats with norzimeldine, a 5-HT uptake inhibitor, which indicates that these compounds are accumulated in the 5-HT nerve terminals by the 5-HT pump. 3 Selectivity was obtained for compounds with dimethyl, monomethyl or unsubstituted p-amino groups. An isopropyl group appears to substitute for the dimethylamino group but with considerably lower potency. Compounds with 2-substitution showed selectivity for aminergic neurones and this effect decreased with increased size of the substituent. The 2,6-dichloro derivative FLA 365 had, however, no neuronal selective action but was a potent MAO inhibitor. Substitutions in the 3- and 5- positions decreased both potency and selectivity. 4 Prolongation ofthe side chain with one methylene group abolished the preference for the MAO in 5-hydroxytryptaminergic neurones although the MAO inhibitory potency remained.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Brain CYP2D6 and Its Role in Neuroprotection Against Parkinson's
    Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease by Amandeep Mann A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Pharmacology and Toxicology University of Toronto © Copyright by Amandeep Mann 2011 Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease Amandeep Mann Doctor of Philosophy, 2011 Graduate Department of Pharmacology and Toxicology University of Toronto Abstract The enzyme CYP2D6 can metabolize many centrally acting drugs and endogenous neural compounds (e.g. catecholamines); it can also inactivate neurotoxins such as 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1,2,3,4-tetrahydroisoquinoline (TIQ) and β- carbolines that have been associated with Parkinson’s disease (PD). CYP2D6 is ideally situated in the brain to inactivate these neurotoxins. The CYP2D6 gene is also highly polymorphic, which leads to large variation in substrate metabolism. Furthermore, CYP2D6 genetically poor metabolizers are known to be at higher risk for developing PD, a risk that increases with exposure to pesticides. Conversely, smokers have a reduced risk for PD and smokers are suggested to have higher brain CYP2D6 levels. Our studies furthered the characterization and involvement of CYP2D6 in neuroprotection against PD. METHODS: We investigated the effects of CYP2D6 inhibition on MPP+-induced cell death in SH-SHY5Y human neuroblastoma cells. We compared levels of brain CYP2D6, measured by western blotting, between human smokers and non-smokers, between African Green monkeys treated with saline or nicotine, and between PD cases and controls. In addition, we assessed changes in human brain CYP2D6 expression with age.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • 2 11/ 7 361Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date - l 6 June 20ll (I6.06.20ll) 2 11/ 7 361 Al (51) International Patent Classification: (74) Agents: KINNAIRD, James et al; 90 High Holborn, A61K 9/14 (2006.01) A61K 9/51 (2006.01) London, Greater London WC1V 6XX (GB). A61K 9/16 (2006.01) A61K 31/4045 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, PCT/GB2010/052053 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 8 December 2010 (08.12.2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (25) Filing Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 0921481 .8 8 December 2009 (08.12.2009) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): VEC- kind of regional protection available): ARIPO (BW, GH, TURA LIMITED [—/GB]; 1 Prospect West, Chippen GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ham Wiltshire SN14 6FH (GB).
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • Monoamine Oxidase Inhibitors Revisited
    64 Review Article Monoamine oxidase Douglas G. Wells FrA~ACS, Andrew R. Bjorksten nsc inhibitors revisited The monoamine oxidase inhibitors (MAOI'S) were de- History veloped during the late 1950's as the first effective Isoniazid and its close relative iproniazid were introduced antidepressant agents. With the development of the for the treatment of tuberculosis in 1951.3 Zeller et al. 4 tricyclic antidepressants, their use was superseded by demonstrated enzyme inhibition of MAO by iproniazid, drugs which appeared to be generally more effective and and in 1957 it was first used for the treatment of lacked the dangerous side effect of hypertensive crises. depression: Iproniazid was withdrawn from the United Recently there has been a resurgence of interest in their States' market in 1960 because of instances of severe and use, prominently for atypical depressions but also for sometimes fatal hepatotoxicity, s Those agents in current anxiety states, obsessive-compulsive disorders, eating use (tranylcypromine, phenelzine, isocarboxazid and disorders, chronic pain syndromes and migraine. 1.2 pargyline, which in the U.S. is approved in the treatment Because of widespread belief among anaesthetists of hypertension only) are the result of efforts to synthesise concerning the likelihood of life-threatening cardiovascu- MAOI's having the benefits of ipronazid without its lar instability and central nervous system (CNS) dysfunc- adverse effects. An often quoted figure is that tranylcy- tion during anaesthesia and surgery when these agents are promine and phenelzine account for over 90 per cent of all present, usual recommendations have been to withdraw the MAOI's currently prescribed. ''7 Because these data them two to three weeks before surgery.
    [Show full text]
  • Stardrop Refernce Guide
    © 2015 Optibrium Ltd. Optibrium™, StarDrop™, Glowing Molecule™, Nova™, Auto-Modeller™, Card View™ and MPO Explorer™ are trademarks of Optibrium Ltd. BIOSTER™ is a trademark of Digital Chemistry Ltd., Derek Nexus™ is a trademark of Lhasa Ltd., torch3D™ is a trademark of Cresset Biomolecular Research Ltd. and Matsy™ is a trademark of NextMove Software Ltd. 1 INTRODUCTION ....................................................................................................................... 5 1.1 StarDrop overview ............................................................................................................................. 5 1.2 Reference guide summary ............................................................................................................... 8 2 PROBABILISTIC SCORING .................................................................................................. 10 2.1 Defining scoring criteria ................................................................................................................. 10 2.2 Importance of uncertainty ............................................................................................................. 14 2.3 Interpreting scores .......................................................................................................................... 16 3 CHEMICAL SPACE AND COMPOUND SELECTION .......................................................... 18 3.1 Introduction ....................................................................................................................................
    [Show full text]
  • 7Th International Congress on Amino Acids and Proteins Vienna, Austria
    Amino Acids (2001) 21: 1–90 7th International Congress on Amino Acids and Proteins Vienna, Austria August 6–10, 2001 Abstracts Co-Presidents: Steve Schaffer, Mobilel, AL, U.S.A. Michael Fountoulakis, Basel, Switzerland Gert Lubec, Vienna, Austria Contents Analysis................................................................................ 3 Biology ................................................................................ 10 Proteomics . 14 Medicine . 22 Metabolism/Nutrition . 25 Neurobiology . 35 Neuroscience . 45 Plant Amino Acids . 56 Physiology/Exercise and Sport . 59 Polyamines . 63 Synthesis . 68 Taurine ................................................................................ 74 Amino Acids Transport . 79 Addendum . 86 3 Analysis Fully automated HPLC based analysis of cysteine and related used for calculation of the degree of substitution in case of compounds in plasma using on line microdialysis as sample peptide-conjugates. The results of amino acid analysis were preparation verified by the data of ES mass spectrometry method. [This study was supported by grants from Hungarian E. Bald Research Fund (OTKA) T 030838, T025834, T032425, F034886 Department of Environmental Chemistry, University of ´Lodz´, and from the Ministry of Education (FKFP/0153/2001).] Poland Low molecular weight thiols play important roles in metabolism and homeostasis. While plasma thiols, including Free and bound cysteine in homocystinuria: assessment of metabolically related cysteine, glutathione, and homocysteine, cysteine and glutathione status are being investigated as potential indicators of health status A. Briddon1, I. P. Hargreaves1, and P. J. Lee2 and disease risk, trace levels, poor stability, and the lack of 1 structural properties necessary for the production of signals Department of Clinical Biochemistry, and compatible with common detection methods have hampered 2 Metabolic Unit, The National Hospital for Neurology and their accurate assessment. The facile oxidation of sulfhydryl Neurosurgery, London, U.K.
    [Show full text]